BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393-396. [PMID: 9607356 DOI: 10.1016/s0360-3016(98)00058-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 2013;4:361-9. [PMID: 24294507 DOI: 10.3978/j.issn.2078-6891.2013.045] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
2 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195-9. [PMID: 15999098 DOI: 10.1038/sj.bjc.6602687] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
3 Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743. [PMID: 16175188 DOI: 10.1038/sj.bjc.6602760] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
4 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(1): 221-222 [DOI: 10.11569/wcjd.v12.i1.221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Golden DW, Novak CJ, Minsky BD, Liauw SL. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol 2012;7:156. [PMID: 22974515 DOI: 10.1186/1748-717X-7-156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41. [PMID: 12630768 DOI: 10.1385/IJGC:32:1:35] [Cited by in Crossref: 66] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
7 Kang YM, Wang H, Li R, Pan G. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat 2021;20:15330338211043030. [PMID: 34617852 DOI: 10.1177/15330338211043030] [Reference Citation Analysis]
8 Parlak C, Topkan E, Onal C, Reyhan M, Selek U. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol 2012;7:37. [PMID: 22429939 DOI: 10.1186/1748-717X-7-37] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
9 Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236-241. [PMID: 23955427 DOI: 10.1002/jso.23392] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 14.0] [Reference Citation Analysis]
10 Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-6. [PMID: 10737382 DOI: 10.1054/bjoc.1999.1035] [Cited by in Crossref: 114] [Cited by in F6Publishing: 111] [Article Influence: 5.2] [Reference Citation Analysis]
11 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
12 Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study. Int J Radiat Oncol Biol Phys 2013;86:96-101. [PMID: 23265573 DOI: 10.1016/j.ijrobp.2012.11.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
13 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, Zhou RH, Lu DQ. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: Results of feasibility study. World J Gastroenterol 2003; 9(11): 2561-2564 [PMID: 14606097 DOI: 10.3748/wjg.v9.i11.2561] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
16 Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-7. [PMID: 14562009 DOI: 10.1038/sj.bjc.6601263] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 6.0] [Reference Citation Analysis]
17 Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP, McWilliams RR, Haddock MG, Hallemeier CL, Truty MJ, Merrell KW. Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Front Oncol 2021;11:651119. [PMID: 34046346 DOI: 10.3389/fonc.2021.651119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fry LC, Mönkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883-890. [PMID: 18266003 DOI: 10.1007/s00423-007-0276-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]